Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme

In the liraglutide clinical trial programme, liraglutide 1.2 and 1.8 mg were found to effectively lower glycated haemoglobin (HbA1c) in patients with type 2 diabetes (T2D). It is unknown whether baseline body mass index (BMI) is a predictor of change in HbA1c observed during a clinical trial with li...

Descripción completa

Detalles Bibliográficos
Autores principales: Montanya, E., Fonseca, V., Colagiuri, S., Blonde, L., Donsmark, M., Nauck, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067695/
https://www.ncbi.nlm.nih.gov/pubmed/26662611
http://dx.doi.org/10.1111/dom.12617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067695/
https://www.ncbi.nlm.nih.gov/pubmed/26662611
http://dx.doi.org/10.1111/dom.12617

Ejemplares similares